Welcome to our dedicated page for Impel Pharmaceuticals news (Ticker: IMPL), a resource for investors and traders seeking the latest updates and insights on Impel Pharmaceuticals stock.
Impel Pharmaceuticals Inc. (symbol: IMPL) is a Seattle-based biopharmaceutical company dedicated to providing groundbreaking therapies for central nervous system (CNS) diseases. Their innovative approach leverages a proprietary nasal drug delivery system known as the POD™ device, which ensures consistent and predictable drug administration to the upper nasal cavity.
Impel's diverse product portfolio is focused on addressing significant unmet medical needs.
- INP104 (POD™ DHE) is in development for the acute treatment of migraine headaches.
- INP103 (POD™ Levodopa) aims to offer relief for Parkinson's disease patients.
- INP105 (POD™ Olanzapine) targets agitation associated with schizophrenia and bipolar disorders.
- INP102 (POD™ Insulin) is being tested in an NIH-funded trial for Alzheimer's disease.
In September 2021, Impel received FDA approval for Trudhesa®, a nasal spray specifically designed for the acute treatment of migraine with or without aura in adults. This marks a significant milestone in their journey to provide effective therapies for CNS conditions.
Despite recent achievements, Impel has encountered financial challenges and has filed for Chapter 11 bankruptcy as part of a strategic decision to maximize value for stakeholders. The company is actively pursuing a sale and has entered into an agreement with JN BIDCO LLC as the 'stalking horse' bidder. Throughout this process, Impel aims to continue operating normally, ensuring minimal disruption to its customers, employees, and other key stakeholders.
For more details, visit Impel Pharmaceuticals Inc.
Impel Pharmaceuticals (NASDAQ: IMPL) has initiated the CALM 201 study, a Phase 2a proof-of-concept trial for its nasal formulation INP105, aimed at treating agitation in adolescents with autism spectrum disorder (ASD). The study compares a single 5mg dose of INP105 to a placebo, utilizing the company's proprietary POD® technology for rapid drug delivery. Results are anticipated by Q1 2023, following the promising Phase 1 outcomes that showed fast peak plasma levels. Autism represents a significant unmet medical need, with millions affected by related agitation episodes.
Impel Pharmaceuticals (NASDAQ: IMPL) announced key findings from the Phase 3 STOP 301 trial at the 64th AHS Scientific Meeting. An oral presentation highlighted that early response to Trudhesa nasal spray, a treatment for migraines, predicts ongoing effectiveness. New analyses also reported long-term patient-reported benefits, such as reduced disability and headache days, with Trudhesa. The drug, utilizing Impel’s Precision Olfactory Delivery technology, aims to offer rapid, effective relief without the side effects of traditional treatments. The study supports Trudhesa's potential as a viable option for migraine sufferers.
Impel Pharmaceuticals (NASDAQ: IMPL) announced that CEO Adrian Adams will present a company overview at the JMP Securities Life Sciences Conference on June 15, 2022, at 2:00 p.m. ET in New York. The event will focus on the company’s development of transformative therapies targeting high unmet medical needs, particularly in the central nervous system. A live webcast will be available on their Investors page, with a replay accessible for 90 days. Impel’s notable product is Trudhesa, a nasal spray for migraine treatment.
Impel Pharmaceuticals (NASDAQ: IMPL) reported a strong Q1 2022 with Trudhesa® achieving 111% growth in total prescriptions compared to Q4 2021. The company generated $1.8 million in net product revenues, an increase from zero in 2021. Research and Development expenses decreased to $3.7 million, while Selling, General and Administrative costs rose significantly to $19.8 million due to commercialization efforts. A $100 million financing agreement with Oaktree Capital extends the cash runway into 2024. The company plans to initiate the INP105 study for Autism Spectrum Disorder in Q2 2022.
Impel Pharmaceuticals (NASDAQ: IMPL) is set to present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 5:00 p.m. ET in Miami. CEO Adrian Adams will provide a company overview, highlighting Impel's focus on transformative therapies for central nervous system diseases. The event will feature a live webcast accessible through their Investor section. Impel is known for its Trudhesa® nasal spray for migraine treatment and is developing INP105 for agitation in autism patients.
Impel Pharmaceuticals Inc. (NASDAQ: IMPL) will host a live webcast on May 16, 2022, at 8:30 a.m. ET to report its Q1 2022 financial results and provide a business update. The call can be accessed via phone or through a live webcast on their investor website. Impel focuses on developing therapies for unmet medical needs, particularly in the central nervous system. Their approved product, Trudhesa™, is a nasal spray for migraine treatment, and they are developing additional treatments for autism-related agitation and Parkinson’s disease.
Impel Pharmaceuticals, formerly Impel NeuroPharma, celebrates its one-year anniversary as a publicly traded company at the Nasdaq closing bell ceremony. The name change reflects a strategic shift, expanding its focus beyond central nervous system disorders to other areas of high unmet medical needs. The company emphasizes the potential of its Precision Olfactory Delivery (POD®) technology, which aims to enhance drug absorption via the upper nasal space. Trudhesa®, its approved migraine treatment, marks a significant milestone in this evolution. Stock trading will continue under the ticker IMPL.
Impel NeuroPharma (NASDAQ: IMPL) celebrates its first anniversary as a public company by ringing the Nasdaq closing bell on April 25, 2022. CEO Adrian Adams highlighted the company's successful launch of Trudhesa®, a nasal spray for treating acute migraines. The product has exceeded early performance expectations, and Impel has secured financing to sustain operations into 2024. The company is committed to addressing unmet medical needs in the central nervous system and is poised for a transformative year in 2022.
Impel NeuroPharma (NASDAQ: IMPL) announced that Adrian Adams, Chairman and CEO, will present a company overview at the 21st Annual Needham Healthcare Conference on April 14, 2022, at 1:30 p.m. ET. The presentation will focus on transformative therapies for central nervous system diseases, highlighting Impel's Precision Olfactory Delivery technology and its approved product Trudhesa for migraine treatment. A live webcast will be available on their website, with a replay offered for 90 days.
Impel NeuroPharma (NASDAQ: IMPL) reported strong growth for Trudhesa™, achieving a 157% increase in prescriptions since year-end 2021, totaling approximately 11,000 prescriptions. The company exceeded its fourth-quarter guidance of 3,000-4,000 prescriptions, generating over 4,200. Impel secured a $100 million royalty and debt agreement, extending its cash runway into 2024. Despite net losses of $24.7 million (Q4) and $76.7 million (full year), the company is optimistic about 2022, projecting Trudhesa prescriptions between 70,000 and 85,000.
FAQ
What is the market cap of Impel Pharmaceuticals (IMPL)?
What is Impel Pharmaceuticals' core focus?
What is the POD™ device?
What is Trudhesa®?
What are the current products under investigation by Impel?
What recent financial steps has Impel taken?
Who is the 'stalking horse' bidder in Impel's sale process?
Will Impel continue its operations during the sale process?
Who is advising Impel during its restructuring?
Who is Impel's current Chief Restructuring Officer?
How can stakeholders get more information about the proceedings?
